Long, GV; Lebbe, C; Atkinson, V; Mandala, M; Nathan, PD; Arance, A; Richtig, E; Yamazaki, N; Robert, C; Schadendorf, D; Tawbi, HAH; Ascierto, PA; Ribas, A; Flaherty, K; Pakhle, N; Masood, A; Gasal, E; Dummer, R.
The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.
J CLIN ONCOL. 2020; 38(15):-ASCO 2020; May 29-31, 2020.; Chicago.
[Poster]
Web of Science